Patents by Inventor Andong Qiu
Andong Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414709Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: June 28, 2023Publication date: December 28, 2023Inventors: Jonathan BARASCH, Andong QIU
-
Publication number: 20230364046Abstract: The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of one or more amino acids.Type: ApplicationFiled: July 19, 2023Publication date: November 16, 2023Inventors: Andong QIU, Andrew BEENKEN, Jonathan BARASCH
-
Patent number: 11730790Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: March 16, 2020Date of Patent: August 22, 2023Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jonathan Barasch, Andong Qiu
-
Publication number: 20210038686Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: March 16, 2020Publication date: February 11, 2021Inventors: Jonathan BARASCH, Andong QIU
-
Patent number: 10829525Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: March 8, 2017Date of Patent: November 10, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan Barasch, Andong Qiu
-
Patent number: 10588937Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: December 12, 2016Date of Patent: March 17, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan Barasch, Andong Qiu
-
Publication number: 20170189482Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: December 12, 2016Publication date: July 6, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan BARASCH, Andong QIU
-
Publication number: 20170190751Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: March 8, 2017Publication date: July 6, 2017Inventors: Jonathan BARASCH, Andong QIU
-
Patent number: 9624281Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: May 21, 2015Date of Patent: April 18, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan Barasch, Andong Qiu
-
Patent number: 9534027Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: GrantFiled: November 21, 2012Date of Patent: January 3, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jonathan Barasch, Andong Qiu
-
Publication number: 20150329607Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.Type: ApplicationFiled: May 21, 2015Publication date: November 19, 2015Inventors: Jonathan BARASCH, Andong QIU
-
Publication number: 20110214190Abstract: A transgenic mammal, including a transgenic mouse, whose genome comprises a transgene, said transgene comprises a neutrophil gelatinase-associated lipocalin (NGAL) promoter gene operably linked to at least one sequence encoding at least one of a fluorescent or bioluminescent protein, wherein the NGAL promoter gene expression in the mouse can be assayed by bioluminescence or fluorescence imaging.Type: ApplicationFiled: March 1, 2011Publication date: September 1, 2011Inventors: Neal PARAGAS, Jonathan Matthew BARASCH, Andong QIU
-
Patent number: 7888025Abstract: Provided is an isolated and purified DNA molecule comprising the coding region of a PCFT cDNA. Also provided is a segment of the above DNA molecule, capable of serving as a primer for amplifying at least a portion of the DNA molecule. Additionally provided is a pair of the above segments that can be used together as forward and reverse PCR primers for amplifying at least a portion of the above DNA molecule. Further provided is an isolated and purified human PCFT protein. Also provided is a method of evaluating the ability of a human to undergo intestinal folate absorption.Type: GrantFiled: March 3, 2008Date of Patent: February 15, 2011Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: I. David Goldman, Andong Qiu
-
Publication number: 20100122355Abstract: A transgenic mammal, including a transgenic mouse, whose genome comprises a transgene, said transgene comprises a neutrophil gelatinase-associated lipocalin (NGAL) promoter gene operably linked to at least one sequence encoding at least one of a fluorescent or bioluminescent protein, wherein the NGAL promoter gene expression in the mouse can be assayed by bioluminescence or fluorescence imaging.Type: ApplicationFiled: July 16, 2009Publication date: May 13, 2010Inventors: Neal Paragas, Jonathan Matthew Barasch, Andong Qiu